Table 3

Relationship between immunoreactivity scores of SOX7, SOX9, SOX10 and clinicopathological features of PCa
Clinical features (Numbers) SOX7 SOX9 SOX10
IRS P IRS P IRS P
 ± s  ± s  ± s
Age (years)
< 70 (75) 3.93 ± 0.219 0.530 7.46 ± 0.268 0.114 2.73 ± 0.215 0.875
≥70 (72) 4.14 ± 0.224 6.68 ± 0.403 2.79 ± 0.295
Serum PSA Levels (ng/ml)
<4 (27) 4.50 ± 0.330 0.021 7.17 ± 0.560 0.968 3.29 ± 0.456 0.025
≥4 (120) 3.34 ± 0.183 7.14 ± 0.251 2.33 ± 0.185
Gleason Score
< 8 (118) 4.09 ± 0.183 0.317 5.93 ± 0.606 0.024 2.66 ± 0.188 0.276
≥8 (29) 3.69 ± 0.322 7.46 ± 0.235 3.14 ± 0.438
Clinical Stage
<T2A(79) 3.95 ± 0.205 0.431 6.39 ± 0.326 <0.001 2.62 ± 0.226 0.498
≥T2A(68) 4.21 ± 0.259 8.25 ± 0.270 2.86 ± 0.269
Pathological Stage
T2A-T2C(86) 4.06 ± 0.209 0.742 7.23 ± 0.282 0.693 3.53 ± 0.214 0.013
T3A-T4(61) 3.95 ± 0.249 7.05 ± 0.381 2.27 ± 0.287
Metstasis
No (119) 4.88 ± 0.179 0.025 7.34 ± 0.240 0.104 2.67 ± 0.186 0.327
Yes (28) 3.75 ± 0.359 6.39 ± 0.611 3.11 ± 0.455

Zhong et al.

Zhong et al. BMC Cancer 2012 12:248   doi:10.1186/1471-2407-12-248

Open Data